A Public Limited Company incorporated in Cyprus under Company Number HE 441027
Acquiring and developing best-in-class healthcare brands, products, services, and technologies all with global market potential.
The Company’s tangible assets include healthcare products together with intangible assets relating to established businesses, services and intellectual properties.
To further develop a growing portfolio of specialised divisions, while ensuring that each is optimised for its project potential.
To identify proprietary technologies and products, provide expertise and funding required to maximise development and value creation for the company and its shareholders.
Meet the Team
Chairman and Chief Executive
With over 45 years’ business experience, Jack established one of the first mobile phone network resellers in the early eighties, which was eventually sold to Hutchison Whampoa and formed part of what became the Orange mobile phone network in the UK.
He is a successful serial entrepreneur and has a history of identifying, developing and leading successful businesses, many from a start-up position. He has held, and currently holds, several executive positions, including CEO on the boards of a number of Companies in both Europe and North America.
David has over 30 years of extensive international leadership serving at the C-Level for a variety of British and American companies, transforming and aligning their strategies, systems, marketing, products and personnel.
With a solid track record of success leading financial growth, digital transformation, and operational change; David has been involved in the development and funding of a number of public and private companies across a variety of B2B and B2C sectors, including digital marketing, magazine publishing, fintech and environmental energy.
With over 45 years of business experience, George brings a wealth of knowledge to the management team. After an initial career start in marketing with Mars Ltd, George became Sales Director of a London based photography processing business, progressing to MD until the business was sold in 1988.
He then moved into Event Management and acted as a consultant to the restaurant, event and licensed premises markets, giving him extensive practical knowledge of company acquisition assessment. He has provided expert consultancy services to several start-up businesses and aided in the efficient restructuring of others.
BreastCheck is a home-based, low-cost, safe, reliable and accurate way to routinely monitor for breast abnormalities. It is an effective first line investigative system as an adjunct to established clinical examination in helping to identify potential breast abnormalities.
BreastCheck testing takes less than 15 minutes. Readings are entered onto the BreastCheck website where test results can be interpreted immediately.
BreastCheck technology has been FDA, CE and UKCA registered, and is expected to be available through pharmacies in the last quarter of 2023.
Davion design, develop, manufacture, and distribute their own brand of transparent face masks which prevent both onward transmission and provide wearer protection against droplets.
Davion transparent masks utilize cutting edge technology; are anti fog, lightweight, washable, reusable and 100% recyclable.
Davion transparent masks are adjustable and lightweight facilitating full facial recognition and ensuring ease of communication in comfort and safety.
Bio-Genex is the Stem Cell research division of Davion Healthcare Plc. The division is focused on developing, patenting and licensing stem cell treatments. It carries out intensive research and development to identify future stem cell based treatments and cures for a variety of conditions from Alzheimer’s to spinal cord injuries.
Bio-Genex secures global patents around the research developments and licence those patents to pharmaceutical companies globally.
Bio-Genex research interests range from the development and testing of new drugs to cell- based therapies in which stem cells are used to replace ailing or destroyed tissue or cells.
Acquiring and developing best-in-class healthcare brands, products, services, and technologies with global market potential.
Building a robust group of healthcare products, delivering maximised value for shareholders, and ensuring on-going business development internationally.
Identifying proprietary technologies and products, and providing the expertise and funding required to maximise their development and create value.